|
Re: five year follow-up results of FinHer(Finnish trial with only 9 weeks of hercepti
This study is very hard to compare with the treatments given in the US in the herceptin adjuvant trials (and even with the HERA trials where dozens of different chemo combinations --or even more--were given before herceptin was given)), as it uses an unusual combination of chemos given before, not during , and then after the herceptin...but the bottomline is they got a similar decrease in recurrence(35-43% better disease free survival depending on whether or not they had lymph node metastasis)by receiving herceptin as well as chemo as the other trials with only 9 weeks of herceptin instead of a year, without the cardiac complications (except in one case) and that er+s and er-s got equal benefit.
There!
|